AGL 37.47 Increased By ▲ 0.22 (0.59%)
AIRLINK 123.40 Decreased By ▼ -0.62 (-0.5%)
BOP 5.85 Increased By ▲ 0.23 (4.09%)
CNERGY 3.72 No Change ▼ 0.00 (0%)
DCL 8.45 Increased By ▲ 0.20 (2.42%)
DFML 40.65 Increased By ▲ 0.38 (0.94%)
DGKC 86.00 Increased By ▲ 0.26 (0.3%)
FCCL 33.19 Increased By ▲ 0.59 (1.81%)
FFBL 66.25 Decreased By ▼ -0.25 (-0.38%)
FFL 10.16 No Change ▼ 0.00 (0%)
HUBC 105.25 Increased By ▲ 2.15 (2.09%)
HUMNL 13.35 Decreased By ▼ -0.05 (-0.37%)
KEL 4.30 Increased By ▲ 0.05 (1.18%)
KOSM 7.24 Increased By ▲ 0.06 (0.84%)
MLCF 38.65 Increased By ▲ 0.35 (0.91%)
NBP 63.70 Decreased By ▼ -1.31 (-2.02%)
OGDC 174.55 Increased By ▲ 0.75 (0.43%)
PAEL 25.11 Increased By ▲ 0.21 (0.84%)
PIBTL 5.80 No Change ▼ 0.00 (0%)
PPL 142.50 Decreased By ▼ -0.20 (-0.14%)
PRL 23.02 Increased By ▲ 0.04 (0.17%)
PTC 15.45 Increased By ▲ 0.34 (2.25%)
SEARL 65.50 Increased By ▲ 0.15 (0.23%)
TELE 7.03 Increased By ▲ 0.03 (0.43%)
TOMCL 36.50 Decreased By ▼ -0.41 (-1.11%)
TPLP 7.30 Decreased By ▼ -0.04 (-0.54%)
TREET 14.20 Decreased By ▼ -0.08 (-0.56%)
TRG 50.90 Increased By ▲ 1.20 (2.41%)
UNITY 26.69 Increased By ▲ 0.54 (2.07%)
WTL 1.25 Increased By ▲ 0.01 (0.81%)
BR100 9,635 Increased By 33.3 (0.35%)
BR30 28,770 Increased By 196.9 (0.69%)
KSE100 90,635 Increased By 348.3 (0.39%)
KSE30 28,344 Increased By 0.7 (0%)

NEW YORK: Wall Street’s main indexes were flat to higher in choppy trading on Friday, with the Nasdaq reversing earlier losses as megacap tech stocks regained ground, while investors also assessed stronger-than-expected US business activity data.

Megacaps Microsoft Alphabet, Amazon.com and Apple rose between 0.7% and 2%, lifting the tech-heavy Nasdaq and helping the S&P 500 pare early losses.

The S&P 500 Technology index reversed early losses, rising 0.1%, while financial stocks were the biggest decliner.

All the three major Wall Street indexes were on track to post weekly gains, with the S&P 500 briefly crossing the 5,500-point milestone during Thursday’s session.

US business activity crept up to a 26-month high in June amid a rebound in employment, but price pressures subsided considerably, offering hope that a recent slowdown in inflation was likely to be sustained.

Flash services PMI increased to 55.1 this month, above expectations of 53.7, while manufacturing PMI edged up to 51.7, compared with expectations of a dip to 51.

May home sales fell to a seasonally adjusted annual rate of 4.11 million units versus expectations of 4.10 million units.

The market is also assessing a string of weakening economic data, and commentary from US Federal Reserve officials this week that interest rates could remain higher for longer if there is no consistent improvement in inflation numbers.

“It certainly looks like at this point the Fed is going to hold tight for a while ... the market is slowly adjusting to that reality,” said Lamar Villere, portfolio manager with Villere & Co.

Money markets are still pricing in a 58% chance of a 25-basis point rate cut in September, and still expect about two rate cuts this year, according to LSEG’s FedWatch data.

AI chip firm Nvidia slipped 0.5%, while semiconductor stocks Qualcomm, Broadcom and Micron Technology were down between 0.2% and 2%.

Wall Street’s bumper gains since the final leg of 2023 have been primarily driven by the likes of Nvidia and a handful of other heavily weighted stocks linked to artificial intelligence. Analysts, however, have raised concerns whether the strong increase in their valuations is sustainable.

Friday’s session will mark the expiry of quarterly derivatives contracts tied to stocks, index options and futures, also known as “triple witching”, adding to market volatility.

At 12:12 p.m. ET, the Dow Jones Industrial Average was down 9.57 points, or 0.02%, at 39,125.19, the S&P 500 was up 2.04 points, or 0.04%, at 5,475.21, and the Nasdaq Composite was up 45.86 points, or 0.26%, at 17,767.44.

Spirit AeroSystems rose 6.1% following a Reuters report that Boeing is nearing a deal to buy back the airplane parts supplier after months of talks.

Sarepta Therapeutics soared 35.2% after the US FDA allowed expanded use of the company’s gene therapy for patients with Duchenne muscular dystrophy aged four and older.

Comments

Comments are closed.